SESSION DETAILS

Parallel Session 1.3

Safeguarding Medicines in the Era of AMR: What Do We Know? What Works?

1 February 2018

14:30 - 16:30 hrs

ROOM :

TBC

BACKGROUND :

The prevention, detection and mitigation of emerging and re-emerging infectious diseases involve both applying preventive controls in animal production as well as ensuring the safety, efficacy, quality, and appropriate use of vaccines, diagnostics and medicines through secure supply chains and health delivery systems.

Complex and fragmented supply chains, especially in countries and regions with limited regulatory and quality oversight, increase the likelihood of substandard, fraudulent or adulterated medicines entering the market.  Poor quality medicines ensure microbial replication in the presence of drug pressure. Substandard and falsified medicines also contribute to lack of efficacy and adverse events, undermining trust in the health system.  Inappropriate use of anti-microbials is another driver of AMR.  Both poor quality medicines and inappropriate use are preventable and can be addressed through the development of robust regulatory and quality assurance systems, treatment guidelines and enforcement.

While there are major limitations in evidence and best practice in the human health sector, even less is known in the veterinary sector, both with respect to use and quality of antibiotics in animals, and effective controls.  Further, environmental factors are beginning to come to light.

 

OBJECTIVES :

  • Review evidence of what is known about the links between medicines quality and AMR.
  • Highlight successful efforts in, and benefits from, strengthening systems that monitor and strive to improve medicines quality.
  • Address environmental impacts of antibiotic manufacturing on AMR.
  • Relate frameworks for addressing medicines quality and appropriate use in the human sector to the animal sector and discern what lessons and approaches from other initiatives could be mobilized to address these drivers of infectious disease risk and AMR.

Moderator

Katherine bond

Vice President, International Regulatory Affairs

U.S. Pharmacopeia

United States of America

Panelist

Angkana Sommanustweechai

Research Fellow

International Health Policy program

Thailand

Margaret Hamburg

President

American Association for the Advancement of Science

United States of America

Michael Deats

Group Lead, Substandard and Falsified Medical Products

World Health Organization

Switzerland

Margareth Ndomondo-Sigonda

Head of Health Programs

New Partnership for Africa's Development

South Africa

Sasi Jaroenpoj

Head of Veterinary Medicinal Product

Department of Livestock Development, Ministry of Agriculture

Thailand

Documents

Documents: PS1.3 Safeguarding Medicines in the Era of AMR: What Do We Know? What Works?
Short Paper: